Proteomic Analyses of Host and Pathogen Responses during Bovine Mastitis by Boehmer, Jamie L.
Proteomic Analyses of Host and Pathogen Responses
during Bovine Mastitis
Jamie L. Boehmer
Received: 10 June 2011 /Accepted: 22 August 2011 /Published online: 4 September 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract The pursuit of biomarkers for use as clinical
screening tools, measures for early detection, disease
monitoring, and as a means for assessing therapeutic
responses has steadily evolved in human and veterinary
medicine over the past two decades. Concurrently, advan-
ces in mass spectrometry have markedly expanded proteo-
mic capabilities for biomarker discovery. While initial mass
spectrometric biomarker discovery endeavors focused pri-
marily on the detection of modulated proteins in human
tissues and fluids, recent efforts have shifted to include
proteomic analyses of biological samples from food animal
species. Mastitis continues to garner attention in veterinary
research due mainly to affiliated financial losses and food
safety concerns over antimicrobial use, but also because
there are only a limited number of efficacious mastitis
treatment options. Accordingly, comparative proteomic
analyses of bovine milk have emerged in recent years.
Efforts to prevent agricultural-related food-borne illness
have likewise fueled an interest in the proteomic evaluation
of several prominent strains of bacteria, including common
mastitis pathogens. The interest in establishing biomarkers
of the host and pathogen responses during bovine mastitis
stems largely from the need to better characterize mecha-
nisms of the disease, to identify reliable biomarkers for use
as measures of early detection and drug efficacy, and to
uncover potentially novel targets for the development of
alternative therapeutics. The following review focuses
primarily on comparative proteomic analyses conducted
on healthy versus mastitic bovine milk. However, a
comparison of the host defense proteome of human and
bovine milk and the proteomic analysis of common
veterinary pathogens are likewise introduced.
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Background
By definition, a biomarker is a characteristic that can be
measured and evaluated as an indicator of normal biolog-
ical processes, pathological processes or pharmacologic
responses to therapeutic interventions. Several applications
for biomarkers have been described, including the use of
biomarkers to diagnose the presence or absence of a disease
[1, 2], predict or evaluate the efficacy of new and existing
drug therapies [3, 4], or to serve as surrogates for
measuring clinical outcomes [5]. To be considered a “good”
biomarker, an indicator of disease must exhibit accuracy,
sensitivity, and specificity. More simply stated, the expression
ofa biomarker mustbespecific toa disease and the biomarker
should remain unchanged during unrelated disorders. Like-
wise,reliableandreproduciblequantificationofthebiomarker
must be demonstrated [6, 7].
The development of soft ionization techniques in mass
spectrometry (MS) including matrix-assisted laser desorption/
ionization (MALDI) and electro-spray ionization (ESI),
enabled the use of MS to characterize biopolymers such as
peptides and proteins, and greatly enhanced proteomic
research [8]. By definition, the term proteomics refers to
the use of a scientific approach to elucidate all proteins
within a cell or tissue at a given time and physiological
condition [9]. Proteomics typically involves the use of
analytical methodologies such as two-dimensional gel
electrophoresis (2D-GE) or liquid chromatography (LC) to
separate proteins or peptides, and MS to isolate, identify, and
characterize proteins and their associated post-translational
modifications (PTMs). Mass spectrometric-based (MS-
based) proteomic methodologies boast several advantages
over earlier protein detection and characterization methods
including the capacity to detect a greater number of proteins
in a given sample, as well as accurate protein identification
and quantification without a reliance on antibodies.
Proteomics likewise offers an advantage over genomic
analyses in biomarkers studies because a weak correlation
often exists between mRNA levels and actual protein
concentration [10–13].
Prior to the dominance of MS-based analytical
approaches in proteomic biomarker studies, most initial
protein analyses involved the use of antibody-based
strategies, namely Western blots and enzyme-linked immu-
nosorbent assays (ELISAs). Though extremely accurate, the
most crucial element of an antibody-based detection
strategy is a highly specific antibody-antigen interaction.
Though a substantial amount of information has been
generated on the expression of cytokines and soluble
mediators of inflammation expressed during intra-
mammary infections in dairy cows using ELISAs specifi-
cally [14], the use of approaches that rely on the availability
of species-specific antibodies limits the identification and
characterization of novel protein candidates in biomarker
discovery analyses. Additionally, very few antibodies are
commercially available for ruminant species as compared to
more traditional laboratory animal species such as mice and
rabbits, which further restricts the number of bovine
proteins that can be analyzed by Western blot or ELISA.
Finally, it has been well established that many proteins are
modified post-translationally during disease, but because
there is no practical protocol for the development of an
immunoassay targeting a modified site if neither the site nor
the modification is known, the use of antibody-based
detection strategies can also limit the detection of potential
disease specific PTMs.
A tremendous amount of research has been dedicated to
elucidating the mechanisms and mediators involved in the
bovine host response to intra-mammary infection with
Gram-positive and Gram-negative pathogens [14]; due
largely to staggering economic losses caused by the disease,
the limited number of efficacious treatment options, and the
lack of accurate biomarkers to evaluate the efficacy of new
animal drugs proposed as primary and adjunctive mastitis
therapies. As well, the prominent use of antimicrobials to
prevent and combat mastitis infections in dairy cattle has
garnered significant attention due to fears regarding the
potential impact of antibiotic use in agriculture and the
emergence of resistant strains of bacteria. Furthermore,
while antibiotics are an effective treatment regimen for
most cases of contagious mastitis caused by Gram-positive
pathogens, several studies have demonstrated that despite
their use, antibiotics have little or no efficacy in treating
clinical or subclinical cases of mastitis caused by environ-
mental or Gram-negative bacteria [15, 16].
The outer membrane of Gram-negative bacteria is
characterized by the presence of lipopolysaccharide (LPS),
a compound known to stimulate a rapid inflammatory
response in the bovine mammary gland [17, 18]. Mastitis
infections caused by Gram-negative pathogens are prob-
lematic to treat, mainly because Gram-negative bacteria are
protected from most antibiotics, detergents and chemicals
by their outer cell-wall. Additionally, antibiotics have no
effect on the deleterious effects of the endotoxin released by
the bacteria. The only treatment that has shown promise as
an adjunctive therapy for the profound intra-mammary
inflammation associated with coliform mastitis is the use of
non-steroidal anti-inflammatory drugs or NSAIDs [19–21].
However, due to the lack of valid criteria to evaluate
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approved for use in lactating dairy cattle. Subsequently, the
need to identify biomarkers to evaluate the efficacy of new
and existing drug therapies and to facilitate new veterinary
drug approvals has provided a stimulus for investigations into
changes in the bovine milk proteome during mastitis.
The biological complexity of bovine milk, including the
numerous reported PTMs of milk proteins, the presence of
multiple variants of the dominant casein proteins, and the
extreme dynamic range of the proteins that comprise bovine
milk, has prevented the extensive characterization of low
abundance proteins present in the bovine milk proteome
[22]. Despite the common proteomic bottlenecks related to
sample complexity, attempts have been made to study the
dynamics of differential protein expression during bovine
mastitis [23–28]. Consequently, over the past 10 years,
significant advances have been made in identifying low
abundance proteins in various bovine milk fractions
collected both before and during clinical mastitis infections
[23–28].
The proteomic analyses of mastitic bovine milk per-
formed thus far have utilized different strategies including
2-dimensional gel electrophoresis (2D-GE) followed by
MALDI-time-of-flight (TOF)/MS, and liquid chromatogra-
phy coupled to tandem mass spectrometry (LC-MS/MS).
Proteomics has been used to evaluate modulation of milk
proteins during mastitis in milk samples collected from
cows with naturally-occurring mastitis infections [23, 24,
29], as well as in milk samples collected before and at time
points following experimental induction of coliform mastitis
by intra-mammary infusion with Escherichia coli or LPS
[25–28]. Additionally, proteomics has been used to investi-
gate proteolysis in bovine milk following infusion with
lipoteichoic acid isolated from Staphylococcus aureus [30],
and comparisons have been drawn between host defense
proteins detected in both human and bovine milk fractions
[31]. Various quantification strategies have likewise been
used to assess modulation in the bovine milk proteome
during mastitis including densitometry [23], spectral count-
ing [26, 27], and incorporation of stable isotopes [28]. In all,
roughly 80 proteins related to the host response to intra-
mammary infections have been robustly identified in bovine
milk as a result of proteomic investigations conducted in the
past 10 years (Table 1).
To a lesser extent, proteomic strategies have also been
applied to the analysis of bovine mammary tissue, but the
reported analyses have focused on profiling enzymes
involved in milk synthesis and the production of milk
lipids, and not on differential protein expression during
mastitis [32, 33]. Other analyses, however, have focused on
the use of proteomics to identify virulence factors, antigenic
proteins, cell wall components, and proteins unique to
select bacterial strains isolated from cases of bovine
mastitis, and have contributed more directly to current
knowledge of pathogen responses during clinical intra-
mammary infections [34–37]. Specifically, proteomic analy-
ses of veterinary pathogens, including etiological agents of
mastitis, have identified potential targets for vaccine devel-
opment, and elucidated potential mechanisms employed by
invading bacteria to survive in the host environment [34–37].
Though still hindered by the dynamic and heterogeneous
cellular composition of the matrix, the use of proteomic
methodologies to obtain a more complete and unbiased
characterization of host and pathogen responses during
clinical mastitis could lead to the identification of a
biomarker, or pattern of biomarkers, indicative of the
disease. Likewise, the characterization of antigens specific
to divergent strains of mastitis-causing bacteria and pathogen
responsestothehostenvironmentcouldprovidethenecessary
targets for the development of new preventatives. Should the
difficulties inherent to the characterization of a complex
proteome be overcome, and the criteria for accuracy,
sensitivity, and specificity met, the establishment of bio-
markers of mastitis would prove useful in evaluating the
efficacy of existing or new drugs to treat secondary
inflammation caused by Gram-negative pathogens, or for the
discovery of potential new drug targets for the treatment of all
intra-mammary infections.
Proteomic Strategies for Biomarker Discovery
The focus of proteomic-based biomarker discovery analy-
ses is typically the identification and characterization of
proteins present in a given biological tissue or fluid, the
assessment of differential protein expression between
different samples, or the detection and evaluation of the
PTMs of target proteins. Accordingly, MS has emerged as
the dominant approach in protein biomarker discovery
analyses. Protein identification through the use of MS can
be divided into two main categories, referred to as top-
down and bottom-up. The primary distinguishing features
between the two proteomic approaches is that a top-down
approach involves the direct ionization and fragmentation
of intact proteins using MS, whereas bottom-up proteomics
entails the proteolytic digestion of protein mixtures fol-
lowed by the chromatographic separation of peptides and
the ionization, fragmentation, and mass analysis of peptides
by MS for protein identification [38, 39]. Another aspect
that differentiates top-down proteomics from the bottom-up
approach is the retention of PTM and cleavage information
of identified proteins when using a top-down approach
versus the loss of such information when dealing with
tryptic peptides in a bottom-up experiment [39]. Top down
methods are likewise based on the principle that the
sequence of any given protein in a sample is available in
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Protein Primary accession
number
Protein name Condition
present
a
Reference
b
Actin related
ACTB P60712 Actin, cytoplasmic 1 M 4, 6
CAP1 Q3SYV4 Adenyl cyclase-associated
protein 1
M6
COF1 Q5E9F7 Cofilin-1 M 6
GELS Q3SX14 Gelsolin M 6
PROF1 P02584 Profilin-1 M 6
Acute Phase
A1AG Q3SZR3 Alpha-1-acid glycoprotein N, M 4,6,8
A1BG Q2KJF1 Alpha-1B- glycoprotein M 8
B2MG P01888 Beta-2-microglobulin N, M 4,6,8
FETUA P12763 Alpha-2-HS-glycoprotein M 4,6,7
HPT Q2TBU0 Haptoglobin M 6,7
SAA P35541 Serum amyloid A M 6–8
Antimicrobial
CTHL1 P22226 Cathelicidin-1 M 4–8
CTHL2 P19660 Cathelicidin-2 M 4–8
CTHL3 P19661 Cathelicidin-3 M 4–7
CTHL4 P33046 Cathelicidin-4 M 4–8
CTHL6 P54228 Cathelicidin-6 M 8
CTHL7 P56425 Cathelicidin-7 M 8
PGRP Q8SPP7 Peptidoglycan recognition
receptor protein
M4 –7
Blood Coagulation
ANT3 P41361 Antithrombin-III M 6,7
ENOA Q9XSJ4 Alpha-enolase M 6
FIBA P02672 Fibrinogen alpha chain M 6,7
FIBB P02676 Fibrinogen beta chain M 4,6,7
FIBG P12799 Fibrinogen gamma chain M 6
KNG1 P01044 Kininogen 1 M 6,7
KNG2 P01045 Kininogen 2 M 6
PLMN P06868 Plasminogen M 6,7
THRB P00735 Prothrombin M 6
Complement & Inflammatory Response
CFAB P81187 Complement factor B M 6
CO3 Q2UVX4 Complement C3 N, M 4,6,7,8
CO4 P01030 Complement C4 M 4,6,7,8
CO9 Q3MHN2 Complement component C9 N, M 8
A7E3S8 A7E3S8 Heat shock 70kD protein M 8
Q3T149 HSPB1 Heat shock protein beta-1 M 8
IGHG2 P01859 Ig gamma-2 chain C region M 7,8
IGJ Q3SYR8 Immunoglobin J chain M 8
Q693V9 Q693V9 Complement component 3d M 7
S10AC P79105 Protein S100-A12 M 4,8
Glycolysis
B4GT1 P08037 β-1,4 galactosyltransferase-1 M 6
G3P P10096 Glyceraldehyde-3-phosphate
dehydrogenase
M6
PGK1 Q3T0P6 Phosphoglycerate kinase-1 M 6
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Protein Primary accession
number
Protein name Condition
present
a
Reference
b
Lipid Related
APOA1 P15497 Apolipoprotein A-1 M 4,6,7
APOC3 P109035 Apolipoprotein C-III M 4,6
FITM2 A4IFN5 Fat storage-inducing
transmembrane protein 2
M6
LIPL P11151 Lipoprotein lipase M 6
LPGDS O02853 Lipocalin-type prostaglandin D synthase M 1
NPC2 P79345 Epididymal secretory protein E1 precursor N 4
PTGDS O02853 Prostaglandin-H2 D-isomerase M 6
Milk Proteins
BT1A1 P18892 Butyrophylin N, M 6
CASA1 P02662 α-S1-casein N, M 3–7
CASA2 P02663 α-S2-casein N, M 3–7
CASB P02666 β-casein N, M 3–7
CASK P02668 κ-casein N, M 1–7
FOLR1 P02702 Folate receptor alpha M 6
GLCM1 P80195 Glycam-1 (Lactophorin) N, M 5,6,8
LALBA P00711 α-lactalbumin N, M 3–7
MFGM Q95114 Lactadherin N 3,4,6,7
TRFL P24627 Lactoferrin N, M 3,6,7,8
Oxidation Reduction
CERU Q9XT27 Ceruloplasmin M 7
PERL P80025 Lactoperoxidase M 6,8
XDH P80457 Xanthine dehydrogenase/oxidase M 6,8
Protease Inhibitors
A1AT P34955 α-1-antitrypsin M 4,6,8
A2MG Q7SIH1 Alpha-2-macroglobulin M 6,8
ITIH1 Q0VCM5 Inter-alpha-trypsin inhibitor heavy chain H1 M 6,8
ITIH4 Q3T052 Inter-alpha trypsin inhibitor heavy chain 4 M 6
Q5J801 Q5J801 Endopin 2B M 7
Transport
ALBU P02769 Serum albumin N, M 1–7
APOA2 P81644 Apolipoprotein A-II M 4,6,7
APOA4 Q32PJ2 Apolipoprotein A-IV M 6,7
APOE Q03247 Apolipoprotein E M 6
FABPH P10790 Fatty acid-binding protein, heart N 4
FETA Q3SZ57 Alpha-fetoprotein M 6
HEMO Q3SZV7 Hemopexin M 6
LACB P02754 β-lactoglobulin N, M 2–7
PIGR P81265 Polymeric-immunoglobin receptor N, M 3,4,6,8
TRFE Q29443 Serotransferrin M 2–7
TTHY O46375 Transthyretin N,M 4
VTDB Q3MHN5 Vitamin D binding protein M 6
Other
ANXA1 P46193 Annexin A1 M 7
APOH P17690 Beta-2-glycoprotein-1 M 6
CD9 P30932 CD9 Antigen M 7
CD14 Q95122 Monocyte differentiation antigen CD14 M 8
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on the detection of a tryptic peptide that must be sorted out
from a complex mixture of peptides [38]. Though gaining
in popularity, top-down proteomics has not yet been applied
to the evaluation of host or pathogen responses during
bovine mastitis, perhaps due to the need for MS instruments
with extremely high mass resolution, accuracy, and the
capability of fragmenting large ions for top-down protein
characterization [39]. Due to relative ease of the method-
ologies, availability of several supportive software options,
the accessibility of numerous suitable instrument systems,
and the establishment of viable quantification strategies,
bottom-up proteomics has dominated biomarker discovery
endeavors related to bovine mastitis. Over the past two
decades specifically, 2D-GE followed by MALDI-TOF/
MS, and LC-MS/MS have become the most widely used
bottom-up proteomic approaches for protein identification
in bovine milk.
Two-Dimensional Gel Electrophoresis (2D-GE)
and MALDI-TOF MS
Protein profiling by 2D-GE is characterized by a first
dimension separation of proteins by isoelectric point,
followed by a second dimension sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS- PAGE) separa-
tion by molecular size. Advances in 2D-GE technology
including gel strips with immobilized pH gradients (IPG) for
isoelectric focusing have dramatically increased the resolving
power and reproducibility of 2D-GE. Additionally, the
development of radioactive and fluorescent labeling has
improved the ability to visualize proteins in a 2D gel, as well
as the detection of low-abundance and post-translationally
modified proteins [40].
In a MALDI-TOF/MS experiment, the protein or peptide
(s) of interest is mixed with a suitable energy-absorbing
matrix and allowed to co-crystallize by air-drying on a
stainless steel plate. In addition to the ability to co-
crystalize with the analyte and absorb the wavelength of
the laser employed, compounds used as MALDI matrices
must also be vacuum stable, soluble in solvents that are
compatible with the sample being analyzed, and must
enable and promote the ionization of the analyte of interest
[41]. Matrices used in MALDI-TOF/MS are typically
highly substituted aromatic molecules with carboxylic acid
moieties capable of absorbing high levels of UV light at a
specific wavelength, such as sinapinic acid, which is
commonly used for the analysis of intact proteins, or
alpha-cyano-4-hydroxycinnamic acid, which is often used
for the MALDI analysis of peptides [41].
The generation of ions in MALDI-TOF/MS is initiated
by short pulse irradiation with a laser, typically nitrogen or
neodymium-doped yttrium aluminum garnet, and occurs
when the matrix becomes electronically excited following
absorption of photons from the UV laser. Proteolytically
digested peptides in the sample accept a proton from the
matrix and become singly charged positive ions as they are
converted into the gas phase and ejected from the matrix.
The ions are then directed into the TOF analyzer where
they are separated by size and generate a mass spectrum.
Separation of ions in a MALDI-TOF experiment occurs due
to the velocity differences that exist between ions once the
pulse of ions exit the ionization source and are dispersed in
time down the flight tube. TOF mass analysis is based on
the principle that after acceleration to a constant kinetic
energy, ions travel at velocities that are inversely related to
the square root of their mass-to-charge (m/z) values [42].
Thus, lighter ions “fly” down the TOF tube and reach the
Table 1 (continued)
Protein Primary accession
number
Protein name Condition
present
a
Reference
b
CH3L1 P30922 Chitinase-3-like protein 1 M 6
CLUS P17697 Clusterin M 6–8
CRF Q3MHN5 Corticoliberin M 6
FGFP1 Q9MZ06 Fibroblast growth factor-binding M 7
H12 P16403 Histone H1.2 M 7
NUCB1 Q0P569 Nucleobindin-1 M 6
OSTP P31096 Osteopontin N, M 6,8
S10A8 P28782 Protein S100-A8 M 6,8
S10A9 P28783 Protein S100-A9 (Calgranulin B) M 6–8
aCondition present; N = normal bovine milk; M = mastitic bovine milk
bReferences; 1 = Baeker et al., 2002; 2 = Hogarth et al., 2004; 3 = Smolenski et al., 2007; 4 = Boehmer et al., 2008; 5 = Boehmer et al., 2010
(25); 6 = Boehmer et al., 2010 (26); 7 = Danielsen et al., 2010; 8 = Hettinga et al., 2011
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subsequent identification of proteins from a MALDI mass
spectrum is accomplished by the comparison of the set of
peptide masses generated from a specific protein, or the
peptide mass fingerprint, to a protein database containing
theoretically calculated mass fingerprints of all known
proteins.
Fragmentation reactions, or post-source decay (PSD),
can often occur during travel down the flight tube of a TOF
MS instrument, possibly due to collisions between ions and
neutral matrix molecules, or between ions and residual gas
molecules [43]. PSD fragment ions can be monitored using
TOF instruments equipped with a reflectron, which is an
electrostatic mirror consisting of a series of electrical lenses
that possess progressively higher repelling potentials [42].
A reflectron not only improves the mass resolution of the
MALDI MS spectrum, but likewise allows for the separation
of PSD fragment ions and the generation of a PSD spectrum,
which can be searched against a protein database to obtain
peptide sequence information. Using a MALDI-TOF instru-
ment, however, requiresthe generationof several PSD spectra
fromdifferentmassregions inorder togeneratefragmentation
information adequate for peptide identification. Subsequently,
the sequencing of peptides using MALDI-TOF MS is most
often performed using instruments equipped with dual TOF
analyzers (MALDI-TOF/TOF). In contrast to single TOF MS
instruments, MALDI-TOF/TOF instruments allow for the
generation of complete fragment ion spectra in a single
acquisition as well as improved precursor ion selection, and
are thus preferable for accurate peptide sequencing using
MALDI [44].
Liquid Chromatography Tandem Mass Spectrometry
(LC-MS/MS)
Despite the recent advancements in reproducibility and
protein quantification, 2D-GE as a means of protein
separation still suffers from issues including diminished
capacity for the isolation of low abundance proteins,
hydrophobic proteins, or proteins with extreme isolelectric
points. Consequently, LC has emerged as the preferred
method for in-solution separation of proteins and peptides
prior to mass analysis using MS. Using the LC-MS/MS
approach, proteins are proteolytically digested into peptides
using a protease such as trypsin, which cleaves at every
arginine and lysine residue, and separated online by 1-
dimensional (1-D) or 2-dimensional (2-D) LC prior to
introduction into the mass spectrometer for mass analysis.
Separation of peptides is accomplished by either strong
cation-exchange chromatography, reverse-phase (RP) chro-
matography, or a combination of both separation strategies,
followed by ionization and mass analysis of the peptides
andpeptidefragmentsbyESI-MS/MS[45]. In traditional 2-D
LC, peptides are separated in the first dimension by charge
using ion exchange chromatography, and are then further
separated in the second dimension by hydrophobicity using
RP-LC. Alternatively, peptides can be separated by 2D-LC
using RP-LC in both dimensions. In 1-D LC-MS/MS
experiments, peptide mixtures are typically separated only
by hydrophobicity by passage over a column packed with
non-polar stationary phase. Using either approach, the
number of proteins identified using LC-MS/MS is directly
dependent on the efficiency of peptide separation prior to
introduction into the mass spectrometer [46]. Poor chro-
matographic resolution increases the frequency of the co-
elution of peptides off the LC column prior to introduction
into the mass spectrometer, which can result in the
production of a tandem mass spectrum of a peptide mixture
that often fails to yield a match when searched against a
protein database. Additionally, the potential for selection of a
peptide from a low abundance protein for further fragmen-
tation by a process called collision-induced dissociation
(CID) will decrease with poor LC peak resolution, and
peptides from dominant proteins will be preferentially
selected for analysis.
In LC-MS/MS experiments, ESI is the dominant method
of ionization. Ionization occurs in ESI after the peptide
solution is dispersed as a fine spray of charged droplets
after passage through a heated metal capillary tube to which
voltage is applied. The charged droplets get desolvated by a
dry inert gas, and multiply charged ions are produced.
Nano-spray ionization (NSI) functions in a manner similar
to ESI, but flow rates from the LC instrument into the
ionization source of the mass spectrometer are much lower
with nano-spray than those used for ESI. Because flow
rates are reduced from microliters per minute to nanoliters
per minute when using nanospray, droplet formation can
occur without the additional of heat or a sheath gas, smaller
charged droplets are formed, and ionization efficiency is
greatly improved [47].
Ions resulting from either ESI or NSI are directed into
the vacuum chamber of the MS instrument, and are
resolved according to their m/z ratio. In tandem mass
spectrometry (MS/MS), the masses of precursor ions are
determined in the first MS scan, and an MS spectrum is
generated. From each MS scan, a pre-determined number of
ions can be selected for further fragmentation by CID.
Fragmentation by CID involves the introduction of an inert
gas such as argon (Ar) or helium (He) into the collision cell
of the mass spectrometer which, through impact with the
selected precursor ions, results in further fragmentation of
the ions. The second stage of tandem MS is used to analyze
the masses of the fragment, or product, ions produced by
CID, and results in the production of a tandem or MS/MS
mass spectrum. Peak lists generated from the fragment ion
masses in tandem mass spectra are then distilled and
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acid sequence of the peptides in the complex mixture. The
assignment of the sequenced peptides to a given protein is
the means by which protein identification is ultimately
accomplished [46].
Common Proteomic Bottlenecks
Comparative proteomic analyses are designed to elucidate
changes in the relative abundance of proteins among
different biological states, most commonly healthy versus
diseased. Detection of the same peptides from a given
protein is not always possible in comparative studies,
however, because PTMs of peptides as a result of disease
is expected. Characterization of PTMs is crucial for
biomarker discovery, because much of the regulation of
the biological activity of proteins is mediated by the
modification of peptide amino acid residues, including the
phosphorylation of serine and threonine, and the glycosyl-
ation of asparagine, arginine, or tyrosine. Unfortunately
characterization of PTMs has been hindered in past experi-
ments due to the fact that modifications are labile and are
often lost in a CID experiment. Electron-transfer dissocia-
tion (ETD), which is a superior fragmentation strategy for
the analysis of PTMs, however, was recently introduced,
and shows promise as a strategy for the characterization of
protein modification during disease [48]. The ETD tech-
nique uses electrons to promote fragmentation along the
peptide backbone, which produces a series of c- and z- ions,
instead of CID fragmentation, which most often produces a
series of b- and y- ions. Protonation during ionization
occurs most often at the N-terminal amino group; however,
the charge can be localized to any of the nitrogen atoms that
comprise the amide bond [42]. As a result, all three of the
peptide backbone bonds can be cleaved, and either the N- or
C- terminus fragments may retain the charge (Fig. 1). When
the charge is retained on the N-terminus, the ions are denoted
as either an, bn,o rcn, whereas C-terminus ions are designated
as xn, yn,o rzn. While side chain information (R group) is lost
during the formation of b- and y- ions, the fragmentation of
the peptide backbone using ETD and the generation of c-
and z- ions allows for amino acid side chains and
modifications such as glycosylation and phosphorylation to
remain intact, making it possible not only to deduce the
amino acid sequence of a peptide, but also to detect any
modified residues [48].
Other limitations that obstruct comparative proteomic
experiments include the types of proteins present in the
sample to be analyzed, protein abundance or dynamic
range, and the chosen proteomic strategy. A select number
of highly abundant proteins can sometimes represent a large
percentage of the total protein concentration in a given
sample, which can lead to a higher probability of selection
of peptides from the abundant proteins for MS/MS analysis,
and hindered detection of low abundant proteins. For
example, serum albumin can account for more than half the
total protein concentration of plasma (30-50 g/L), whereas
minor proteins such as interleukins are present in only
picogram concentrations [49]. However, identification of
low abundance proteins is critical to biomarker discovery, as
low-copy-number gene products have a high probability of
being potential drug targets and biological markers of disease
[50].
Preparation strategies are typically employed to deplete
high abundance proteins prior to LC-MS/MS in an effort to
reduce sample complexity and enhance detection of low
abundance proteins. Some traditional depletion strategies
include the precipitation of abundant proteins, the use of
size exclusion filters or 1D-SDS PAGE to fractionate a
complex mixture of intact proteins by mass, and targeted
removal of abundant proteins using immuno-depletion
techniques. There are several commercially available
depletion kits optimized for use with serum and plasma
that selectively deplete a number of the most abundant
blood proteins including serum albumin, immunoglobulins,
complement, and acute phase proteins. Additionally, the use
of a bead-bound library of peptides with random rearrange-
ments of six amino acids and the capacity for binding a
large number of different proteins is gaining popularity as a
means to equalize the abundance of proteins in a complex
biological sample [51].
Specific depletion techniques used in prior proteomic
analysis of bovine milk have included acid precipitation of
the casein proteins [23, 28, 29], and the use of bead-bound
peptide libraries [27]. When considering comparative
proteomic analyses of normal and mastitis milk, however,
the divergence that exists in the number of hydrophobic and
hydrophilic proteins in a given sample at each physiological
state, the varying sizes and charge states of proteins present
in each matrix, PTMs, and the cellular distribution of
proteins in one sample versus another makes the application
of a universal sample preparation strategy extremely
unfeasible. Additionally, though depletion strategies are
commercially available, they are often optimized for only
Figure 1 Diagram of N- and C- terminus fragment ions generated
from all three (3) possible cleavages of peptide backbone bonds
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of samples, most notably bovine milk, and can lead to
the non-selective depletion of proteins of potential
interest [27]. Likewise, profound changes in the dynamic
range, modification, and protein composition of a given
sample due to the induction of a disease such as mastitis
can further confound the use of sample preparation
strategies [27]. When no effective sample preparation
strategy is applicable, several proteomic approaches are often
combined to increase protein detection and subsequent
proteome coverage. For example, LC techniques are more
efficient for detection of hydrophobic, low molecular mass,
and basic proteins than 2D gel based methods, whereas 2D-
GE enables the detection and visualization of PTMs [50].
Despite limitations and inherent drawbacks, proteomic
strategies offer a wider range of capabilities than classic
approaches to protein characterization such as ELISA and,
with further advances, could factor prominently in the
establishment of biomarkers of mastitis.
Quantification
Advances in MS have provided a means for the accurate
and sensitive identification of differentially expressed
proteins in complex biological samples, but another
important criterion for the establishment of disease bio-
markers is reliable quantification. Relative and absolute
quantification of modulation in protein abundance using
proteomic strategies is a topic that has garnered significant
attention in recent years [52–55]. Proteomic-based quanti-
fication methods can be assigned to one of two broad
categories: the incorporation of stable isotope labels into
proteins or peptides prior to MS analysis, or the alternative,
which is to use a label-free quantitative method [55].
The basis of most labeled quantification methods is the
theory that a labeled peptide will behave in the same
fashion chemically as its unlabeled counterpart, and
therefore the two peptides will have identical chromato-
graphic and MS properties [55]. The addition of a label,
however, does impart a mass difference between the two
peptides, and thus relative abundance can be inferred by
comparing the respective signal intensities of the labeled
and unlabeled peptides in the same MS run [55]. Labels can
be incorporated in several ways, with the most popular
means being either metabolically, chemically, or enzymat-
ically [53, 55]. Examples of labeling strategies include:
metabolic labeling commonly known as stable isotope
labeling by amino acids in cell culture or SILAC [56];
proteolytic labeling with
18O[ 57]; or isotope incorporation
by several means including chemical derivatization also
known as isotope coded affinity tags or ICAT [10], isobaric
tags for relative and absolute quantitation (iTRAQ) [58], or
global internal standard technology [59].
The derivatization of the primary amine groups of
proteins or peptides with isobaric tags, or iTRAQ, has
become a very popular LC-MS/MS quantification strategy
in recent years. Quantification using iTRAQ is performed
by the fragmentation of the attached isobaric tag, which
generates a low molecular mass reporter ion [58]. The
popularity of iTRAQ in proteomic screens, including the
analysis of mastitis pathogens [36], the bovine milk fat
globular membrane [60], and bovine milk following in vivo
LPS challenge [28], is due primarily to the capacity to
simultaneously analyze four or more of differential protein
pools.
However, though very accurate, labeling strategies can
be cost-limiting, unsuitable for some types of biological
matrices, and cannot be performed retrospectively. In terms
of comparative proteomic analysis of normal versus
mastitic milk aimed at biomarker discovery, labeling
strategies are not always feasible for protein quantification.
Due to dramatic changes in protein composition during
clinical mastitis, accurate comparisons of the abundance of
a peptide that is present at one physiological state but not
the other is problematic [27]. As a result, label-free
strategies, which are based on the correlation between the
abundance of a protein or peptide in a sample and the MS
signal [55], have increased in popularity in recent years. Ion
intensity, determined by extracted ion chromatograms
(XIC), is one of the most accurate and widely used methods
of label-free quantification. Using XIC, the number and
intensity of selected precursor ions at a particular m/z are
summed, and the peaks areas used as a measure of relative
abundance [61]. Another popular label-free approach is
spectral counting, which is defined as the number of MS/MS
spectra that contribute to the identification of a given protein
[62, 63]. Spectral counting is based on the assumption that
the abundant proteins, when proteolytically digested, will
yield numerous copies of the same peptide, and that peptides
from abundant proteins have higher probabilities of trigger-
ing multiple MS/MS events than peptides from lower
abundance proteins. Similar to spectral counts, the number
of unique peptides assigned to each protein in a sample has
likewise been used as a measure of relative protein
abundance [26, 62]. An inherent drawback of label-free
methods, though, is the assumption that the linearity of
response will be the same for each protein, which often does
not hold true because the chromatographic behavior of
peptides tends to vary [55]. Additionally, because the amino
acid composition of every peptide differs, the ionization
potential of each peptide is unique, and may not always be
correlated to abundance. Thus, many spectra must be
acquired and data normalized when using label-free methods
[61]. Nevertheless, label-free quantification does not require
any extra sample processing and can be performed retrospec-
tively; two attributes which make non-labeled quantification
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discovery research [55].
Modulation in the Bovine Milk Proteome
During Mastitis
Proteomic strategies were first applied to the study of the
bovine milk proteome in the late 1980s, and were
predominantly focused on analysis and characterization of
the most abundant milk proteins. The initial proteomic
ventures utilized either 2D-GE or LC alone, and were
performed only on bovine whole milk [64–66]. Similarly,
the earliest attempt to identify bovine milk proteins via LC
coupled with MS was limited to the detection of only the
major milkproteinsβ-lactoglobulin, α-lactalbumin,α-casein,
β-casein, and κ-casein, and lacked peptide sequencing data
[67]. More recently, however, proteomics has been used to
characterize and, in some studies quantify, changes in the
bovine milk proteome that represent the host response to
infection [23–29].
Initial Comparative Proteomic Analyses of Bovine Milk
The first proteomic endeavor aimed at the identification of
novel markers for bovine mastitis was a comparison of
differentially expressed proteins in normal and mastitic
bovine milk from seven cows with naturally-occurring
clinical infections using 2D-GE followed by MALDI-TOF-
MS PSD [29]. Milk sample preparation prior to proteomic
analysis was relatively simple, and consisted of removal of
the milk fat by centrifugation at 4°C, and acid precipitation
of the caseins. The results of the proteomic analyses
indicated the isolated presence of lipocalin-type prostaglandin
D synthase in 2D gels generated from milk samples collected
from cows with clinical mastitis [29]. Other proteins detected
in the 2D-GE profiles of the milk samples analyzed included
serum albumin and κ-c a s e i n[ 29]. Though the results were
extremely limited and only a single differentially expressed
protein in mastitic bovine milk was reported, the study
nonetheless marked the first instance of published data on a
marker of inflammation identified in bovine milk during
mastitis using proteomic strategies.
A later attempt to identify differentially expressed
proteins in whey from healthy cows versus cows with
clinical mastitis also employed 2D-GE followed by enzy-
matic digestion of isolated proteins and MALDI-TOF-MS
[22]. Mastitis was defined strictly by identification of
clinical signs and milk sample preparation prior to analysis
included fat removal and precipitation of the casein proteins
by the addition of salt, followed by dialysis to remove
traces of the ammonium sulphate [23]. Despite attempts to
remove the casein fraction from the milk prior to proteomic
analysis, however, αS1-casein, β-casein, and κ-casein were
still found in rather high abundance in normal milk. Also
identified were the proteins serum albumin, transferrin,
microsomal triglyceride protein, β-lactoglobulin, and α-
lactalbumin [23]. Marked increases in serum albumin and
transferrin, concurrent with apparent decreases in the
caseins, β-lactoglobulin, and α-lactalbumin were apparent
in the 2D-GE profiles generated from whey samples from
cows with mastitis, and supported the well established
theory that serum protein concentration increases in milk
during clinical mastitis infections as a result of the
breakdown of the blood-milk barrier [23]. While no
additional biomarker information was gained and protein
identification was restricted to major milk proteins, the
results were the first to demonstrate temporal changes in
bovine milk protein expression during mastitis without a
reliance on antibody-based strategies.
Detection of Proteins Related to the Host Response
in Bovine Milk
The first extensive report of protein modulation in separate
sub-cellular fractions of bovine milk collected during
different physiological states included direct LC-MS/MS,
as well as 2D-GE, excision of protein spots, and identifi-
cation by either MALDI-TOF-MS or LC-MS/MS [24]. The
milk fractions analyzed included milk from a cow in peak
lactation, colostrum from a fresh cow, and milk from a cow
with naturally-occurring clinical mastitis. Though the
sample size was limited, the results of the analyses were
the most comprehensive to date in terms of the number of
low abundance proteins indentified, and the number of host
response proteins that were isolated from mastitic milk
[24]. An additional novel aspect to the proteomic analyses
conducted by Smolenski and colleagues was the fact that no
sample clean-up or attempts to deplete high abundance
proteins were carried out on the samples prior to analysis.
Despite the presence of caseins in the fractions analyzed,
the study marked the first reported identification of proteins
such as apolipoprotein A-1, cathelicidin-1, heat shock
protein 70kD protein, peptidoglycan recognition receptor
protein (PGRP), calgranulin B and C, and serum amyloid A
(SAA) in milk fractions collected from a cow with
naturally-occurring mastitis [24].
The first reported comparison of protein expression
patterns in milk from cows before and after experimental
induction of E. coli mastitis utilized 2D-GE followed by
peptide sequencing using MALDI-TOF PSD to characterize
differentially expressed proteins [25]. Unlike prior 2D-GE-
MALDI analyses of mastitic bovine milk, no removal of
high-abundance proteins was performed prior to analysis.
The analyses involved milk samples collected from 8 cows
before, and at 18 h following intra-mammary inoculation
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all 8 cows were sequenced to avoid reporting a protein that
represented a potentially unique response to infection.
Despite the lack of sample clean-up, the low abundance
proteins transthyretin, lactadherin, β-2-microglobulin pre-
cursor, α-1-acid-glycoprotein (A1AG), and complement C3
precursor were identified in whey samples from healthy
cows. Wheysamples at18 h postinfection were characterized
by an abundance of serum albumin, in spots of varying mass
and isoelectric point, as well as increased transthyretin and
complement C3 precursor levels. Also detected at 18 h post
inoculation were the antimicrobial peptides (AMPs) catheli-
cidin −1, −2, −3, and −4, and the proteins β-fibrinogen, α-2-
HS-glycoprotein, S100-A12, and α-1-antiproteinase [25].
The most notable results of the analyses, however, were the
detection of the cathelicidin cationic AMPs, and the
identification of the acute phase protein (APP) A1AG in
both normal and mastitic whey samples, as discoveries of the
AMPs and A1AG were not reported in previous comparative
2D-GE proteomic analyses of bovine milk [23, 24, 29]. As
well, prior reports of APP expression in milk during bovine
mastitis were all antibody-based detections, and only
documented the identification of the APPs SAA, haptoglobin
(HPT), and lipopolysaccharide binding protein [68–70].
Temporal Expression and Quantification of Bovine Milk
Protein Modulation during Clinical Mastitis
The first proteomic analyses of a more extensive longitu-
dinal series of bovine milk samples collected from 8 mid-
lactation cows before and over the course of experimental
infection with E. coli, utilized an ultra pressure LC
instrument coupled to a quadrupole TOF-MS [26]. Similar
to earlier analyses [24], only a select number of proteins
related to the host response were identified in whey from
milk following E. coli challenge. LC-MS/MS conducted on
whey from milk samples collected just prior to infusion
with E. coli and at various time points following infection
resulted in the identification of the high to medium
abundance proteins αS1-, αS2- β-, and κ-casein, and the
whey proteins serum albumin, β-lactoglobulin and α-
lactalbumin. Additionally, a select number of lower
abundance markers of inflammation including lactoferrin,
transferrin, apolipoprotein A-I, fibrinogen, Glycam-1,
PGRP, and cathelicidin-1 were also identified. Despite
limited protein identifications, normalized peptide counts
for each protein identified were used to evaluate temporal
changes in milk proteins following infection [26]. Addi-
tionally, to assess the accuracy of LC-MS/MS-based label-
free quantification strategies, modulation in the abundance
of serum albumin, lactoferrin, and transferrin in milk during
disease evaluated using proteomic-based methods were
compared with protein abundance measured using ELISAs.
The outcome of the comparison of label-free, proteomic-
based quantification with abundance profiles generated by
ELISAs revealed that label-free LC-MS/MS methods
yielded results that were both comparable to antibody-
based detection, and a viable means of tracking changes in
relative protein abundance in milk during disease [26].
Despite the identification of primarily abundant milk
proteins, the results likewise indicated that, with further
methodology refinement, LC-MS/MS could be used to
evaluate temporal changes in proteins related to host
response for which no antibody existed [26].
More recent comparative proteomic analyses of whey
from bovine milk before, and at time points after
experimental challenge with E. coli [27] or LPS [28], have
resulted in the more robust detection of bovine milk
proteins, including the identification of a greater number
of proteins related to the host response to infection. The
separate comparative analyses both involved evaluation of
samples collected before and following experimental
induction of clinical mastitis, both reported quantification
of changes in the relative abundance of milk proteins
related to host response, and both detected equivalent
numbers and types of proteins (Table 1). The distinguishing
factor between the two comparative proteomic analyses was
the application of the iTRAQ labeling strategy for quantifica-
tion of protein modulation [28], versus the use of spectral
counts, a label-free proteomic approach, to assess changes in
the relative abundance of minor milk proteins [27]. Other
divergent aspects of the in-vivo challenge studies included
the number of animals enrolled in each study, as well as
sample preparation strategies. Methodologies employed in
the proteomic analysis of host response to LPS-mediated
intra-mammary inflammation differed slightly from previous
E. coli challenge studies [25–27] in that only 3 cows were
enrolled in the study, and acid precipitation of caseins was
performed prior to LC-MS/MS analyses.
Similar to the prior reports on the use of label-free
quantification strategies [26], the accuracy of LC-MS/MS
label-free quantification performed using samples collected
in the E. coli challenge study was compared to data
generated using antibody-based strategies [27]. Unlike prior
reports, however, total spectral counts were used as a
measure of relative abundance and, due to increased
sensitivity of the instrument system, the temporal expres-
sion of the low abundance acute phase proteins HPT and
SAA were evaluated as opposed to major milk proteins
[27]. Comparisons of ELISA data and total spectral counts
for the two APPs revealed trends in temporal expression
with very similar overall patterns, which reaffirmed the
utility of using LC-MS/MS data to model expression
patterns of proteins related to the host response in bovine
milk during clinical mastitis. Conversely, quantification of
hostresponsestoLPS-mediatedinflammationwerecalculated
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for peptides identified in pre-challenge milk samples and time
points following challenge [28].
Though the time frame of the reported modulation in
protein expression differed due to inoculation with E. coli
versus purified LPS, which is known to stimulate a more
rapid inflammatory response than E. coli in the bovine
mammary gland [18], and the methods of determining
changes in protein abundance were not the same, the
identified proteins with altered expression patterns were
similar for the two separate analyses. Proteins related to the
host response to infection detected in whey from bovine
milk at time points following infection were predominantly
vascular derived, acute phase, antimicrobial, complement,
or related to immune response, and fell into categories that
could be broadly classified as secondary effects of cytokine
induction [27, 28]. Cytokine expression during the bovine
innate immune response to invading pathogens has been
well characterized, and the induction of vascular leak and
APP synthesis, as well the stimulation of neutrophils as a
result of cytokine production have been previously estab-
lished [14]. Following intra-mammary inoculation with E.
coli, several vascular-derived proteins including all three
chains of the blood coagulation protein fibrinogen, apoli-
poprotein A-1, and serotransferrin were detected in bovine
milk as early as 12 h after challenge, with peak abundance
detected at 24 h following induction of mastitis [27]. The
same proteins were detected following challenge with LPS,
and were 2-fold or higher in expression level 7 h after
infusion [28]. Similarly, peak expression of complement C3
determined using spectral counts, was detected in bovine
milk 18 h after induction of coliform mastitis [27], while 2-
fold changes in reporter ion intensity was apparent for
complement C3 peptides in bovine milk 7 h after LPS
challenge [28]. The reported increases of serum proteins in
milk following E. coli or LPS challenge are most likely
results of vascular leakage induced by tumor necrosis
factor-alpha (TNF-α) or interleukin-1 beta (IL-1β) expres-
sion, and corresponded well with prior reports of peak
cytokine expression during E. coli and LPS induced
mastitis [14, 18]. In all, 13 of the same proteins were found
to have biologically relevant changes in relative abundance
during clinical mastitis in both comparative proteomic
analyses, including complement factors, the AMPs
cathelicidin-1 and PGRP, apolipoprotein A-1, the APPs
serotransferrin, HPT, and SAA, and the somewhat poorly
characterized proteins kininogen, inter-alpha-trypsin inhibitor
heavy chain-4 (ITIH4), and clusterin [27, 28].
The most interesting aspect of both quantitative proteomic
analyses of bovine milk following experimental induction of
mastitis was the modulation of apolipoproteins and the
somewhat novel candidate biomarkers ITIH4, kininogen,
and clusterin. Quantification of changes in abundance of the
potentially novel candidates was accomplished using both
iTRAQ [28] and spectral counts [27]. The temporal
expression patterns of the candidate proteins, modeled using
LC-MS/MS spectral count data (Fig. 2), likewise appeared to
be in accord with prior reports of inflammatory mediator
expression during coliform mastitis [14]. Though apolipo-
proteins are known to be involved in lipid transport and are
major components of high density lipoproteins, other roles
for the apolipoproteins during disease and inflammation have
been proposed [71]. The specific role of the apolipoproteins
during inflammation related to coliform mastitis has not yet
been determined, but implications are that the apolipopro-
teins could inhibit neutrophil activation, as well as the release
of inflammatory cytokines [72, 73]. By similarity, bovine
ITIH4 is assumed to be a serine protease inhibitor involved
in the acute phase response. Reports of ITIH4 expression in
cattle, however, have been limited to isolation of the APP
from the serum of heifers with experimentally induced
summer mastitis [74]. Prior to recent comparative proteomic
analyses of bovine milk following in vivo challenge, ITIH4
was never identified in bovine milk, and its exact role during
coliform mastitis remains unknown. Kininogen, on the other
hand, belongs to the family of plasma kallikreins, and is
known to play key roles in complement activation [75], and
the release of bradykinin [76]. Bradykinin levels in milk
from cows with experimentally induced coliform mastitis
have yet to be investigated, but the kinin peptides are
presumed to be potent mediators of vasodilation, pain, and
udder edema during clinical mastitis [77]. Similar to ITIH4,
the function of clusterin during coliform mastitis also
remains unclear. Prior reports have indicated that clusterin
could possess anti-inflammatory properties [78, 79], but the
only inference in regards to the role of clusterin in the bovine
mammary gland is that clusterin could be associated with
mammary gland involution, the clearance of cellular debris,
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analyses are required, the results of the comparative
proteomic analysis of bovine milk during experimentally-
induced clinical mastitis have provided information that
could prove useful in the design and execution of future
studies, and have shed light on potential candidates for the
establishment of inflammatory biomarkers in bovine milk.
Comparison of Host Defense Proteomes of Human
and Bovine Milk
Associations between proteins related to the host defense
present in human and bovine milk have recently been
reported [31]. The total numbers of proteins identified
following proteomic analyses of both human and bovine
milk differed by only one protein, and more than half of the
reported proteins were detected in samples from both
species [31]. Using LC-MS/MS, analyses of whey from
milk and the milk fat globular membrane from both human
and bovine milk resulted in the identification of 44 proteins
related to the host response in human milk fractions, and 51
host defense proteins in the equivalent bovine samples.
Thirty-three (33) defense-related proteins were identified in
milk fractions from both species, and included several
APPs, complements factors, members of the cathelicidin
family of cationic AMPs, clusterin, immunoglobins, osteo-
pontin, several mucins, lactoferrin, calgranulins, as well as
protease inhibitors [31]. Though similar proteins were
detected in the human and bovine milk fractions, the
abundance and distribution of the proteins differed between
the two species. Specifically, the authors noted the higher
prevalence of antibacterial proteins in the bovine milk
fractions, compared to a marked increase in the detection
and abundance of immunoglobins in human milk fractions
[31]. Possible explanations for the differential prominence
of AMPs, including lactoperoxidase in bovine milk, and
immunoglobins in human milk, were higher thiocyanate
levels in the ruminant diet and differences in immune
system development in human babies and bovine calves,
respectively [31].
Comparative Proteomic Analyses of Mastitis Pathogens
Compared to proteomic analyses of bovine milk and the
genomic analyses of common food-borne and mastitis
pathogens, only limited data exists regarding changes in
the proteomes of common mastitis pathogens isolated from
mastitic bovine milk. The limited number of proteomic
analyses conducted on prevalent mastitis pathogens is most
likely explained by the prior emphasis on genomic
analyses, as well as the fact that comparative proteomics
is still an emerging technology in food animal research and
veterinary medicine. Alternatively, the dominance of
comparative bovine milk analyses could be explained by
the relative ease of sample collection and the ability to
obtain much larger sample volumes.
To date, reports of the proteomic analysis of pathogens
specifically isolated from cases of clinical mastitis have
been limited to an investigation into the cell wall
components of S. aureus isolated from bovine mastitis
[34], proteomic analysis of changes in E. coli when grown
in milk and laboratory media [36], serological proteome
analysis of immunogenic proteins from a strain of S. aureus
isolated from cows with sub-clinical mastitis [35], and the
proteomic characterization of different bovine mastitis S.
aureus isolates [37].
A focus on virulence factors and cell wall components of
S. aureus have predominated proteomic analyses of mastitis
pathogens due primary to the fact that S. aureus is the most
common Gram-positive etiological agent of contagious
bovine mastitis. Additionally, the surface-associated secre-
tory products, leukotoxins, and enterotoxins expressed by
S. aureus represent potential targets for mastitis vaccine
development. Surface components of mastitis pathogens are
of particular interest due to the role these proteins play in
the adhesion of invading bacteria to bovine mammary
tissue, and the resulting potential for resistance to phago-
cytosis by host milk cells [81]. In an initial proteomic
characterization of S. aureus isolated from bovine mastitis,
the majority of the proteins identified by 2D-GE followed
by MALDI-TOF MS were classified as either cell wall or
membrane-associated proteins [34]. A specific discovery,
however, included the detection of DnaK in bovine mastitis
S. aureus isolates, a major surface-exposed antigen that
could be involved in the recognition of epithelial cell
receptors [34].
Serological proteome analysis of bovine mastitis S.
aureus isolates utilized 2D-GE followed by MALDI-TOF
MS, and resulted in the identification of the three highly
immunogenic proteins DNA translocase FtsK, ribosomal
protein S1, and a Tell-like protein [35]. Detection of DNA
translocase FtsK was noteworthy, as the protein is required
for DNA replication, recombination, and transfer within
and between cells, and could potentially be involved in
peptidoglycan synthesis [82, 83]. Likewise, the antigenic
properties of ribosomal protein S1 have been reported [82],
and Tell-like proteins were previously classified as both
virulence and drug-resistance factors [84].
The most recent proteomic analysis of bovine mastitis S.
aureus isolates also employed 2D-GE followed by MALDI-
TOF MS for protein detection and identification. However,
the study focused on the comparative analyses of 17
different S. aureus strains isolated from cows with clinical
and sub-clinical mastitis [37]. Results of the proteomic
comparison of divergent bovine mastitis S. aureus strains
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across the majority of the strains including alkyltransferase-
like protein, zinc metalloproteinase aureolysin, glycerophos-
phodiester phosphodiesterase, lipoteichoic acid synthase,
pyruvate dehydrogenase, and stringent starvation proteins A
and B [37]. Conversely, there were 15 proteins that exhibited
variable expression patterns across the isolates analyzed
including the serine proteases spore photoproduct lyase B, C,
and F, and the superantigens toxic shock syndrome toxin-1,
staphylococcal enterotoxin C, formyl peptide receptor-like-1
inhibitory protein, hyaluronate lyase precursor A1 and A2,
and penicillin-binding protein 2 [37]. Data generated by the
comparative proteomic analyses of the different S. aureus
strains isolated from cows with clinical mastitis not only
supported prior theories that superantigens possess immuno-
modulatory effects and play an important role in mastitis
pathogenesis, but will most certainly factor into future
endeavors to characterize host-specificity of S. aureus
isolates as well as targets for vaccine development [37].
Though there are numerous reports of the proteomic
analyses of E. coli isolates, one study in particular focused
on changes in the E. coli proteome when a strain isolated from
a case of bovine mastitis was grown in fresh milk versus
laboratory media [36]. The results of the comparative
proteomic analyses of E. coli grown in different types of
inhibitory media was the detection of several proteins that
could represent specific mechanisms by which E. coli evades
host immune detection and survives in the bovine milk
environment. Findings that indicated mechanisms by which
the bacteria adapted in order to survive in bovine milk
included the up-regulation of several proteins in E. coli grown
in fresh bovine milk including β- galactosidase, an enzyme
involved in lactose metabolism, up-regulation of siderophores
involved in iron-chelation, as well as increased expression of
LuxS, an enzyme that is critical for the synthesis of bacterial
hormone-like compounds involved in inter-bacterial commu-
nications [36]. Additionally, all of the identified flagellar
proteins were down-regulated, including flagellin, which has
been identified as a ligand for toll-like receptor 5. Down-
regulation of flagellin could represent a way the bacteria
escape detection by the host immune system [36].
Summary and Conclusion
The identification of all proteins that comprise the bovine
milk proteome, the discovery and establishment of bio-
markers indicative of clinical mastitis, and a more complete
understanding of pathogen responses in the host environ-
ment during clinical mastitis infections have been hindered
by several analytical challenges. Caveats to the use of
proteomic strategies for the discovery of biomarkers of host
and pathogen responses during mastitis include the lack of a
universal sample preparation strategy capable of overcoming
the complexity of the biological matrices both before and
during disease, the intense dynamic range of proteins present in
the bovine milk proteome, protein identification reports based
on the use of different sample preparation strategies and
instrument systems, each with associated strengths and weak-
nesses, and the intrinsic variability apparent across biological
replicates during in-vivo challenge models. Notwithstanding
inherent drawbacks, the data generated during recent proteomic
analyses of modulation in host and pathogen responses during
clinical mastitis has expanded current knowledge of the
biological mechanisms involved in bovine mastitis, and
revealed several possible candidate biomarkers of the disease.
Though the future development and validation of a single
biomarker specific to bovine mastitis may not be feasible,
establishment of protein expression profiles indicative of the
host response during clinical mastitis infections could prove
valuable for early disease detection, as well as for distinguish-
ing between local and systemic responses to infections caused
by divergent bacterial pathogens. Protein biomarker profiles
couldalsoserveasameanstoevaluateresponsetotreatments,
and could aid in the review and approval of new veterinary
therapeutics. Because mastitis is associated with profound
inflammation and pain that severely compromise the health
and wellbeing of infected animals, the establishment of a
protein biomarker or biomarker profile could also have a
substantial impact on animal welfare when used for early
detection. Likewise, should the use of proteomic strategies
enable the direct detection and quantification of a protein
biomarkerinbovinemilk,the biomarkercouldbeusedforon-
line surveillance when incorporated into automated milking
systems. Though further evaluations are needed and additional
refinement to sample preparation and analysis strategies is
required, the results of the proteomic analysis conducted to
date on bovine milk and etiological agents of the disease have
provided information that could prove useful in the design and
execution of future studies of inflammatory biomarkers in
bovine milk, and have identified targets for therapeutic and
vaccine development that merit more focused hypotheses-
driven analyses.
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